Skip to main content
. 2023 Jan 17;13:1080501. doi: 10.3389/fimmu.2022.1080501

Table 1.

Monocyte subpopulations` content in healthy individuals and CRC patients.

Subpopulations Healthy donors
(N=42)		 Cancer patients
Colorectal cancer
(N=70)		 Colon cancer
(N=42)		 Rectal cancer
(N=28)
CD14+CD16-, % 82,06
(71,36-85,13)		 83,49
(77,21-88,25)		 84,89
(77,33-88,43)		 82,66
(76,36-86,35)
CD14+CD16+, % 2,35
(1,89-4,16)		 2,74
(2,3-7,3)		 2,79
(1,8-4,12)		 2,69
(1,93-4,1)
CD14-CD16+,% 5,99
(2,75-8,02)		 4,62
(1,98-7,33)		 3,62
(1,72-7,28)
p=0,04 		5,94
(3,38-7,6)
CD14+CD16-CD163+,% 95,27
(85,44-98,73)		 89,79
(73,93-99,2)		 94,44
(73,93-99,37)		 87,53
(77,5-97,36)
CD14+CD16-CCR2+,% 61,00
(45,58-79,53)		 70,12
(29,58-91,4)		 68,47
(40,93-80,65)		 85,94
(19,09-95,11)
CD14+CD16+CD163+,% 94,51
(86,89-97,87)		 92,81
(81,9-96,45)		 92,8
(83,89-96,45)		 93,13
(80,81-96,18)
CD14+CD16+CCR2+,% 18,04
(11,88-41,84)		 18,95
(10,77-48,47)		 23,48
(6,55-51,85)		 10,17
(2,96-18,55)
CD14-CD16+163+,% 42,12
(20,43-85,77)		 56,73
(23,51-58,19)		 58,88
(26,88-94,3)		 43,15
(21,14-65,17)
CD14-CD16+CCR2+,% 4,39
(0,65-7,17)		 5,85
(0,69-6,83)		 7,25
(0,97-12,43)		 2,96
(0,47-12,69)

p – difference between colon and rectal cancer groups.